From: Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
Year | 1999-2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009-2010 |
---|---|---|---|---|---|---|---|---|---|---|
Non-epileptic MS relapses | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 |
Brain MRI activity (new T2 or Gd + lesions or both) | + | - | + | - | - | n.d. | - | n.d. | + | - |
EDSS score | - | 0 | 1 | 1 | 2 | 2 | 2.5* | 3* | 4** | 2.5* |
MS therapy | - | - | GA | GA | GA | GA | GA | GA | GA | Natalizumab |
Partial seizures | 1 (onset) | 1 | 4 | 4 | 6 | 8 | 7 | 8 | 10 | 4 |
Generalized seizures | 1 (onset) | 1 | 3 | 2 | 3 | 6 | 5 | 5 | 7 | 0 |
Status epilepticus | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
AEDs (daily dose in mg) | Â | VPA 600 | VPA 1000 | VPA 1000 | VPA 1000 | VPA 1300 | VPA 1000 | KEP 3000 | KEP 3000 | KEP 1000 |
 |  |  | CBZ 300 | CBZ 800 | CBZ 1200 | CBZ 1400 | LMT§ | OXC 2100 | OXC 2400 | GBP 900 |
 |  |  |  |  |  |  | TOP 250 |  | GBP 900 |  |